Ding Ming-Xia, Luo Xin, Zhang Xue-Mei, Bai Bing, Sun Ju-Xiang, Qi Hong-Bo
Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Obstetrics and Gynecology, Linyi People's Hospital, Linyi, China.
Taiwan J Obstet Gynecol. 2016 Jun;55(3):399-404. doi: 10.1016/j.tjog.2015.07.005.
No treatment is recommended for routine maintenance tocolysis after an arrested preterm birth. Our present study aimed to evaluate the effect of progesterone and nifedipine as maintenance tocolysis therapy after an arrested preterm birth.
For relevant studies, we systematically searched the literature in databases of PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library. Only randomized controlled trials were included.
Nine trials were included in our review. Nifedipine and progesterone were used for maintenance tocolysis. Compared to placebo treatment or no treatment, maintenance tocolysis with progesterone could significantly prolong the delivery gestational weeks [standard mean difference (SMD) 1.64; 95% confidence interval (CI), 1.21, 2.07; p < 0.00001], reduce the proportion of patients with delivery before 37 weeks (risk ratio 0.63; 95% CI, 0.47, 0.83; p = 0.001), and increase the birth weight (SMD 317.71; 95% CI, 174.89, 460.53; p < 0.0001). However, no such benefits were observed after maintenance tocolysis with nifedipine. Both nifedipine and progesterone had no significant influences on the following outcomes: neonatal intensive care unit stay, proportion of neonatal intensive care unit admission, neonatal mortality, and incidence of respiratory distress syndrome.
Our results with maintenance tocolysis with progesterone may be useful for patients who had an episode of threatened preterm labor successfully treated with acute tocolytic therapy.
对于早产停滞后的常规维持性宫缩抑制治疗,不推荐进行任何治疗。我们目前的研究旨在评估孕酮和硝苯地平作为早产停滞后维持性宫缩抑制治疗的效果。
对于相关研究,我们系统检索了PubMed、Embase数据库以及Cochrane图书馆的Cochrane对照试验中心注册库(CENTRAL)中的文献。仅纳入随机对照试验。
我们的综述纳入了9项试验。使用硝苯地平和孕酮进行维持性宫缩抑制治疗。与安慰剂治疗或不治疗相比,孕酮维持性宫缩抑制治疗可显著延长分娩孕周[标准均差(SMD)1.64;95%置信区间(CI),1.21,2.07;p < 0.00001],降低37周前分娩患者的比例(风险比0.63;95% CI,0.47,0.83;p = 0.001),并增加出生体重(SMD 317.71;95% CI,174.89,460.53;p < 0.0001)。然而,硝苯地平维持性宫缩抑制治疗后未观察到此类益处。硝苯地平和孕酮对以下结局均无显著影响:新生儿重症监护病房住院时间、新生儿重症监护病房入院比例、新生儿死亡率和呼吸窘迫综合征的发生率。
我们关于孕酮维持性宫缩抑制治疗的结果可能对那些曾因早产先兆而成功接受急性宫缩抑制治疗的患者有用。